Topotecan

• Description :

  Topotecan (SKF 104864A; NSC 609669) is an orally active and potent Topoisomerase I inhibitor. Topotecan induces cell cycle arrest in G0/G1 and S phases and promotes apoptosis. Topotecan shows anticancer activity[1].

• Product Name Alternative :

  SKF 104864A; NSC 609669

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Apoptosis; Autophagy; Topoisomerase

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Autophagy; Cell Cycle/DNA Damage

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/topotecan.html

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O

• Molecular Formula :

  C23H23N3O5

• Molecular Weight :

  421.45

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Zhang FL, et al. PLoS One. 2013 Nov 26;8 (11) :e81815.Topoisomerase I inhibitors, Shikonin and Topotecan, inhibit growth and induce apoptosis of glioma cells andglioma stem cells.|[2]Kumar S, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011 Sep 1;17 (17) :5656-67.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Topo I

• Citation 01 :

  Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|bioRxiv. 2023 Apr 14.|Cancer Immunol Res. 2023 May 3;11 (5) :583-599.|Cancers (Basel) . 2021 Dec 31;14 (1) :193.|Cell Commun Signal. 2024 Jun 13;22 (1) :325.|Cell Death Dis. 2024 Jan 18;15 (1) :66.|J Biomed Inform. 2023 Jun:142:104383.|J Exp Clin Cancer Res. 2018 Dec 20;37 (1) :321. |J Immunol. 2022 Jul 1;209 (1) :171-179.|Nat Commun. 2019 Aug 21;10 (1) :3761.|Pharmaceutics. 2022 Nov 24;14 (12) :2595.|Phytochemistry. 2021 Nov:191:112910.|Sci Rep. 2019 Oct 22;9 (1) :15099. |Biochem Pharmacol. 2023 Oct:216:115769.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|bioRxiv. 2025 Sep 21.|Cancer Res. 2023 Dec 15;83 (24) :4015-4029.|Cell Rep Med. 2025 Apr 2:102053.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2025 Jan 11;44 (1) :115171.|Cell Rep. 2025 Mar 25;44 (4) :115466.|Eur J Med Chem. 2024 Dec 5:279:116842.|FASEB Bioadv. 2020 Mar 7;2 (4) :254-263.|Indiana University Indianapolis. 2025.|Int J Mol Sci. 2025 Apr 17;26 (8) :3790.|J Extracell Vesicles. 2022 Apr;11 (4) :e12206.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|J Nat Prod. 2025 Mar 28;88 (3) :688-705.|J Transl Med. 2024 Aug 14;22 (1) :766.|J Virol. 2019 May 15;93 (11) :e02230-18.|Nat Commun. 2025 Jun 2;16 (1) :5126.|NPJ Precis Oncol. 2024 Jun 5;8 (1) :128.|Pharmacol Res. 2024 May 9:204:107208.|Universitat Autònoma de Barcelona. Biologia Molecular i Biomedicina. 2022 Aug.

• CAS Number :

  [123948-87-8]